Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F12%3A43901007" target="_blank" >RIV/00064173:_____/12:43901007 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.crvasa.2011.12.004" target="_blank" >http://dx.doi.org/10.1016/j.crvasa.2011.12.004</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.crvasa.2011.12.004" target="_blank" >10.1016/j.crvasa.2011.12.004</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents

Popis výsledku v původním jazyce

The treatment of acute coronary syndromes (ACS) is currently undergoing an interesting evolution due to the introduction of some novel antithrombotic drugs. The available evidence on new oral antiplatelet agents can be summarized as follows: (1) the newdrugs (prasugrel and ticagrelor) are faster, more potent, and more predictable than clopidogrel, and thus prasugrel or ticagrelor may replace clopidogrel in most patients with ACS; (2) prasugrel seems to have a more pronounced acute effect, especially inpatients with acute ST-elevation myocardial infarction (STEMI), and thus prasugrel may be the preferred drug for STEMI, especially for the acute phase; (3) ticagrelor seems to have better secondary preventive effects in the long term, which may be advantageous for patients with acute non-STEMI; and (4) both new drugs have some contraindications or unpleasant side effects and are both substantially more expensive, which may keep a place in therapy for clopidogrel for selected patients

Název v anglickém jazyce

Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents

Popis výsledku anglicky

The treatment of acute coronary syndromes (ACS) is currently undergoing an interesting evolution due to the introduction of some novel antithrombotic drugs. The available evidence on new oral antiplatelet agents can be summarized as follows: (1) the newdrugs (prasugrel and ticagrelor) are faster, more potent, and more predictable than clopidogrel, and thus prasugrel or ticagrelor may replace clopidogrel in most patients with ACS; (2) prasugrel seems to have a more pronounced acute effect, especially inpatients with acute ST-elevation myocardial infarction (STEMI), and thus prasugrel may be the preferred drug for STEMI, especially for the acute phase; (3) ticagrelor seems to have better secondary preventive effects in the long term, which may be advantageous for patients with acute non-STEMI; and (4) both new drugs have some contraindications or unpleasant side effects and are both substantially more expensive, which may keep a place in therapy for clopidogrel for selected patients

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cor et Vasa

ISSN

0010-8650

e-ISSN

—

Svazek periodika

54

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

7

Strana od-do

"e32"-"e38"

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—